Bio-Techne to Buy Clinical Standards Provider
President and CEO Charles R. Kummeth. Cliniqa CEO Kevin Gould will remain with the company.
Clinical Controls accounts for around 12% of Bio-Techne total revenues, which totaled $358 million in fiscal 2014. This is Bio-Techne’s first acquisition following the four completed last year (see IBO 4/15/14, 6/30/14, 7/15/14, 11/15/14).
Minneapolis, MN 6/5/15—Bio-Techne has agreed to acquire Cliniqa, a manufacturer of quality controls, calibrators and bulk reagents for the clinical diagnostic market, with a primary focus on blood chemistry. Financial details were not disclosed. Cliniqa has 75 employees. “I am very pleased with this acquisition as it strengthens not only our Clinical Controls product portfolio, but also our reach into the IVD/Clinical Diagnostics segment as well as our management team,” commented Bio-Techne
